Journal Article Reviews Research Using Oxycyte and PFCs in TBI and Decompression Sickness
COSTA MESA, Calif.--(BUSINESS WIRE)--Jan 30, 2009 - Oxygen Biotherapeutics, Inc. (OTCBB:OXBO) announced that an article published yesterday by the Journal of Applied Physiology discusses research conducted with Oxycyte® in Traumatic Brain Injury (TBI) and decompression sickness. Oxycyte is the Company's perfluorocarbon (PFC) therapeutic oxygen carrier.
The article, “Perfluorocarbon Emulsions as a Promising Technology: A Review of Tissue and Vascular Gas Dynamics,” discusses the fundamental knowledge gained regarding how respiratory gas movements are changed when intravenous PFC is present and says that a “particularly promising area of research is the treatment of gas embolism (arterial and venous emboli/decompression sickness).”
It was written by Bruce D. Spiess, MD, FAHA, Professor of Anesthesiology and Emergency Medicine, Director of Virginia Commonwealth University Reanimation Engineering Shock center (VCURES). Dr. Spiess is a member of the Oxygen Biotherapeutics, Inc. board of directors.
“In this article, Dr. Spiess makes an excellent case for potential future indications to be treated with ˜new generation' PFCs,” said Chris J. Stern, DBA, Oxygen Biotherapeutics, Inc. chairman and CEO. “With numerous citations, this underlines the clinical importance of Oxycyte oxygen superchargers as enhancers of all respiratory gas movements. In its section about N2 solubility of Oxycyte, the article highlights the potential of our compound to be used for decompression sickness. All in all, this is an outstanding scientific reference for our product,” said Stern.
Dr Spiess notes: “Cutting-edge research has allowed us to learn how perfluorocarbon emulsions have a unified way of carrying important gases (based on Henry's law) involved in human metabolism. It is those unifying theories that this article stresses. The reader will see that by proper application, taking advantage of the theories, perfluorocarbon emulsions will create a revolution in medicine. We are on the verge of being able to treat traumatic brain injury, stroke, spinal cord injury, sickle cell disease, decompression sickness, sudden death and other medical events with a new technology.”
About Oxygen Biotherapeutics, Inc.
Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and continuous substrate monitoring. The Company has under development a perfluorocarbon therapeutic oxygen carrier and liquid ventilation product (Oxycyte®) and an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs and medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including traumatic brain injury, sickle cell crisis pain, trauma, wound care, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, and diabetes.
Contact: Abe Wischnia & Associates
Abe Wischnia, 619-795-2345
Posted: January 2009